A major regulatory achievement has been reached, signaling progress into the clinical phase of development for a new RNAi therapy. This therapy utilizes a unique systemic treatment delivery method to target common KRAS-driven cancers, which currently lack effective medical solutions. This milestone signifies a step forward in tackling these prevalent cancers and addressing the significant treatment gaps in this area.